Literature DB >> 11087895

Werner's syndrome cell lines are hypersensitive to camptothecin-induced chromosomal damage.

P Pichierri1, A Franchitto, P Mosesso, F Palitti.   

Abstract

Werner's syndrome (WS) is a recessive human genetic disorder associated with an elevated incidence of many types of cancer. The WS gene product, WRNp, belongs to the RecQ family of DNA helicases and is required for the maintenance of genomic stability in human cells. A possible interaction between helicases and topoisomerases that could co-operate in many aspects of DNA metabolism such as progression of the replication forks, recombination and repair has been recently suggested. In addition, sgs1 gene product in yeast, homologous to WS gene, has been shown to physically interact with topoisomerase types I and II. Earlier data from our laboratory suggested that WRN helicase might play a role in a G2 recombinational pathway of double strand breaks (DSBs) repair, co-operating with topoisomerase II. In this work, the effect of the topoisomerase I inhibitor camptothecin in WS cells has been investigated at the chromosomal level. The data from the present work suggest that the inhibition of topoisomerase I activity by camptothecin results in a higher induction of chromosomal damage in WS cell lines in the G2-phase and in the S-phase of the cell cycle compared to normal cells, perhaps associated with the defects in DNA replication synthesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087895     DOI: 10.1016/s0027-5107(00)00109-3

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  23 in total

1.  Werner's syndrome protein is required for correct recovery after replication arrest and DNA damage induced in S-phase of cell cycle.

Authors:  P Pichierri; A Franchitto; P Mosesso; F Palitti
Journal:  Mol Biol Cell       Date:  2001-08       Impact factor: 4.138

Review 2.  Repair of topoisomerase I-mediated DNA damage.

Authors:  Yves Pommier; Juana M Barcelo; V Ashutosh Rao; Olivier Sordet; Andrew G Jobson; Laurent Thibaut; Ze-Hong Miao; Jennifer A Seiler; Hongliang Zhang; Christophe Marchand; Keli Agama; John L Nitiss; Christophe Redon
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

3.  WRN exonuclease activity is blocked by DNA termini harboring 3' obstructive groups.

Authors:  Jeanine A Harrigan; Jinshui Fan; Jamil Momand; Fred W Perrino; Vilhelm A Bohr; David M Wilson
Journal:  Mech Ageing Dev       Date:  2006-12-20       Impact factor: 5.432

4.  Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.

Authors:  Ruben Agrelo; Wen-Hsing Cheng; Fernando Setien; Santiago Ropero; Jesus Espada; Mario F Fraga; Michel Herranz; Maria F Paz; Montserrat Sanchez-Cespedes; Maria Jesus Artiga; David Guerrero; Antoni Castells; Cayetano von Kobbe; Vilhelm A Bohr; Manel Esteller
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-24       Impact factor: 11.205

5.  WRN controls formation of extrachromosomal telomeric circles and is required for TRF2DeltaB-mediated telomere shortening.

Authors:  Baomin Li; Sonali P Jog; Sita Reddy; Lucio Comai
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

6.  The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.

Authors:  Federico Innocenti; Snezana Mirkov; Ramamoorthy Nagasubramanian; Jacqueline Ramírez; Wanqing Liu; Wasim K Bleibel; Sunita J Shukla; Kathleen Hennessy; Gary L Rosner; Edwin Cook; M Eileen Dolan; Mark J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  2008-08-02       Impact factor: 3.333

7.  WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.

Authors:  Markus Christmann; Maja T Tomicic; Christopher Gestrich; Wynand P Roos; Vilhelm A Bohr; Bernd Kaina
Journal:  DNA Repair (Amst)       Date:  2008-10-15

8.  Way out/way in: How the relationship between WRN and CDK1 may change the fate of collapsed replication forks.

Authors:  Valentina Palermo; Sara Rinalducci; Massimo Sanchez; Francesca Grillini; Annapaola Franchitto; Pietro Pichierri
Journal:  Mol Cell Oncol       Date:  2016-12-09

9.  Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.

Authors:  Matt L Harlow; Nichole Maloney; Joseph Roland; Maria Jose Guillen Navarro; Matthew K Easton; Susan M Kitchen-Goosen; Elissa A Boguslawski; Zachary B Madaj; Ben K Johnson; Megan J Bowman; Maurizio D'Incalci; Mary E Winn; Lisa Turner; Galen Hostetter; Carlos María Galmarini; Pablo M Aviles; Patrick J Grohar
Journal:  Cancer Res       Date:  2016-10-03       Impact factor: 12.701

10.  WRN helicase and FEN-1 form a complex upon replication arrest and together process branchmigrating DNA structures associated with the replication fork.

Authors:  Sudha Sharma; Marit Otterlei; Joshua A Sommers; Henry C Driscoll; Grigory L Dianov; Hui-I Kao; Robert A Bambara; Robert M Brosh
Journal:  Mol Biol Cell       Date:  2003-12-02       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.